Folfirinox in locally advanced pancreas adenocarcinoma: Back to the future?

Oncologist

Volumn 18, Issue 5, 2013, Pages 487-489

  Bekaii Saab, Tanios ^a   Goldberg, Richardm M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

CHEMOTHERAPY; FOLLOW UP; HUMAN; INCIDENCE; MORTALITY; NOTE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE;

CAMPTOTHECIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS;

EID: 84878209380     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0157     Document Type: Note

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA CancerJ Clin 2013;63:11-30.
2. Conroy T, Desseigne F, Ychou M et al. FOLFIRI- N OX versus gemcitabine for metastatic pa ncreatic cancer. N Engl JMed 2011;364:1817-1825.
3. Von Hoff DD, Ervin TJ, Arena FP et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine a lone in patients with metastatic adenocarcinoma of the pancreas (MPACT) JClin Oncol 2012;30:(LBA148).
4. Huguet F, Girard N, Guerche CS et al. Chemo- radiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic r eview. J Clin Oncol 2009;27;2269-77.
5. Faris JE, Blaszkowsky LS, McDermott S et al. FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience. The Oncologist 2013;18: 543-548.
6. Hosein PJ, Macintyre J, Kawamura C et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreaticadenocarcinoma. BMCCancer 2012;12:199.
7. Boone B, Stevie J, Krasinskas A et al. Outcomes with FOLFIRINOX for locally advanced pancreatic cancer. JClin Oncol 2012;30 (suppl 34; abstr256).
8. Mahaseth H, Kauh JS, Brutcher E et al. Safety and efficacy of modified FOLFIRINOX in pa ncreatic cancer: A retrospective experience. J Clin Oncol 2012:30 (suppl; Abstr e14614).
9. Peddi PF, LubnerS, McWilliams Retal. Multi- institutional experience with FOLFIRINOX in pan- creaticad enocarcinoma. J OP 2012;13:497-501.
10. Gunturu KS, Thumar JR, Hochster HS et al. Single institution experience with FOLFIRINOX in advanced pancreatic adenocarcinoma (PC). J Clin Oncol 2012;30 (suppl 4; ab str 330).
11. Lowery MA, Yu KH, Adel NG et al. Activity of frontline F OLFIRINOX (FFX) in stage I ll/I V pancreatic adenocarcinoma (PC) at MSKCC. J Clin Oncol 2012;30: abstr 4057.
12. Vasile E, De Lio N, Cappelli C et al. Neaoad- juvant modified FOLFOXIRI in locally advanced pancreatic cancer [abstract 714P]. Ann Oncol 2012;23(suppl9): ix238.
13. Mathey L, Sa-Cunha A, Blanc J F et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicentric prospective study [abstract 716P]. Ann Oncol 2012;22 (suppl 9): ix238.
14. Chang DK, Johns AL, Merrett ND et al. Margin clearance a nd outcome in resected pancreatic cancer. JC lin Oncol. 2009;27:2855-62.
15. Kayahara M, Funaki K, Tajima H et al. Surgical implication of micrometastasis for pancreatic cancer. Pancreas. 2010;39:884-8.
16. Huguet F, André T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase lia nd III studies. JC lin Oncol. 2007;25:326-31.
17. Haller DG, Cassidy J, Clarke SJ et al. Potential regional differencesfor the tolerability profiles of fluoropyrimidines. JC lin Oncol. 2008;26:2118-23.
18. Jones S, Zhang X, Par sons DW et al. C ore signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806.
19. Tuveson DA, Neoptolemos JP. Understanding metastasis in pa ncreatic cancer: A call f or new clinical approaches. Cell 148:21-23.
20. Alberts SR. Upda te on the optimal mana gement of patients with colorectal liver meta stases. Crit Rev Oncol Hematol. 2012;84:59-70.